- Home
- TRNR vs VRAX Comparison
TRNR vs VRAX Comparison
Compare TRNR & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | VRAX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.9M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TRNR | VRAX |
|---|---|---|
| Price | $0.62 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 2.6M | 483.1K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,774,000.00 | $2,986.00 |
| Revenue This Year | $245.67 | $217,274.83 |
| Revenue Next Year | $308.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.36 | N/A |
| 52 Week Low | $0.61 | $0.26 |
| 52 Week High | $39.60 | $2.29 |
Technical Indicators
Market Signals| Indicator | TRNR | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 32.38 |
| Support Level | $0.64 | $0.26 |
| Resistance Level | $1.62 | $0.30 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.66 | 6.54 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).